Ontario Expands Access to Dexcom G7 CGM Under the Ontario Drug Benefit (ODB) Program

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Positive)

Tags

07/30/2025 - 08:00 AM

New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes.

BURNABY, British Columbia--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 Continuous Glucose Monitoring (CGM) System as part of the Ontario Drug Benefit (ODB) program for eligible Ontarians who manage their diabetes with insulin.*

Ontario residents eligible for ODB and living with type 1 or type 2 diabetes and using insulin are now covered for Dexcom G7.

Diabetes Canada estimates that 1.7 million people in Ontario are living with diabetes in 2024, with a significant portion requiring insulin for either type 1 or type 2 diabetes¹. This highlights a broad need for support across both types of diabetes for insulin therapy optimization.

This coverage expansion will grant access to Dexcom G7 to a broader population and make Dexcom G7 now the most covered CGM on government-funded programs in Ontario^†,2 for people on insulin through the following programs:

Ontario Drug Benefit (ODB) – for eligible residents on insulin aged 65+ or earlier if they:

Live in a long-term care home, home for special care, or Community Home for Opportunity
Are 24 or under without private insurance (OHIP+)
Receive professional home and community care
Get benefits from Ontario Works or ODSP
Are enrolled in the Trillium Drug Program

Assistive Devices Program (ADP) – for individuals with type 1 diabetes who meet the eligibility criteria.

Private Insurance – most private insurance plans cover Dexcom G7 for anyone on insulin.

Non-Insured Health Benefits (NIHB) – for eligible First Nations and Inuit clients on insulin.

“This announcement represents a significant step forward for people managing diabetes in Ontario and their healthcare providers with more equitable access to Dexcom’s life-changing CGM technology,” says André Côté, Vice President and General Manager of Dexcom Canada. “By expanding coverage for Dexcom G7 under ODB, Ontario is recognizing the value of the #1 preferred glucose sensor by Canadian endocrinologists^{‡, 3} for the management of insulin-using patients.”

Dexcom G7 is the most accurate CGM with clinically proven outcomes^§,2including lowering A1C, reducing hyper-and hypoglycemia, and increasing time in range for people with type 1 or type 2 diabetes^4-8. Featuring several unique alerts supporting safer insulin therapy, this increased access to Dexcom G7 is welcome news for both healthcare providers and their patients using insulin.

“As an endocrinologist, I’ve seen firsthand how continuous glucose monitoring has transformed diabetes management,” says Dr. Alexander Abitbol, Endocrinologist & Assistant Medical Director, LMC Healthcare. “Managing diabetes is very personal, and being able to offer patients a choice on the most appropriate CGM technology with features tailored to help them meet their individualized care goals is critical.”

Dexcom G7 allows individuals to easily see their glucose levels in real-time to make more informed insulin treatment decisions. Users can see directly how medications affect their levels and gain insights on what keeps their levels stable, empowering them to learn what works in order to feel their best and stay motivated over time.

Discreet and easy to use, Dexcom G7 is the only sensor in Canada to offer these features for insulin therapy optimization and personalization for any lifestyle:

Predictive Urgent Low Soon^||alert that can warn in advance of severe hypoglycemia⁹
Delay 1^st High alert after a meal that may help reduce insulin stacking^10,11
Waterproof sensor
Fast 30-minute sensor warm-up time
Multiple sensor wear locations^#
Direct to Apple Watch functionality^**– user can see glucose numbers right on their wrist

As the #1 patient recommended CGM in Canada^††,12, Dexcom G7 delivers both clinical and lifestyle benefits, and now more Ontarians than ever will have access to this technology for their diabetes management.

To learn more about Dexcom G7 and the public and private coverage options available, please visit dexcom.com.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in continuous glucose monitoring for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

Category: IR

_______________________________________
* For ODB eligible persons who are on insulin therapy for diabetes and who have a valid prescription for Dexcom G7 from a physician or nurse practitioner. Limit of 45 Dexcom G7 Sensors per eligible person per 365-day period. Dexcom G7 Receivers are also covered if there is no compatible smart device. For detailed coverage criteria, please visit https://www.dexcom.com/en-CA/coverage/ontario-provincial-cgm-coverage.
† Dexcom G7 is the only CGM covered by ODB, ADP, most private insurance & NIHB for people on insulin. Eligibility and coverage vary by policy, plan, and payor. For insurance assistance call Dexcom Canada at 1-844-832-1810 with any questions.
‡ Based on a survey of Canadian Endocrinologists (n=41)
§ When compared with CGM systems commercially available in Canada as of October, 2023. Sensors worn on the back of the upper arm have been found to be slightly more accurate than sensors worn on the abdomen.
\|\| Audible and visual notification of predictive alert at 3.1 mmol/L within 20 minutes.
The Dexcom G7 Sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed.
# Indicated for wear on the back of the upper arm and abdomen for ages 2 years and older or the upper buttocks for ages 2-6 years old.
** Smart device sold separately. To view a list of compatible devices, visit dexcom.com/compatibility. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch.
†† Based on a comparison in NPS scores across major CGM brands
1 https://www.diabetes.ca/getmedia/b4f2add1-c56b-48e5-93cd-beb9feebb667/2024-Backgrounder-Ontario.pdf
2 Dexcom, data on file, 2025
3 Q&A, Dexcom Canadian Endos Report Wave 1 2024
4 Beck, RW, et al. JAMA. 2017;317(4):371-378.
5 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.
6 Martens T, et al. JAMA. 2021;325(22):2262-2272.
7 Laffel LM, et al. JAMA. 2020;323(23):2388-2396.
8 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7.
9 Dexcom G7 User Guide.
10 Aly A, et al. Diabetes Technol. Ther. 2024;26(S2): A254-255.
11 Puhr S, et al. Diabetes Technol Ther. 2019;21(4):155-158.
12 DQ&A, Canada Diabetes Connections Patient Panel Report, H1 2024